The economy has reached a critical inflection point, with widespread consumer distress and a stalling labor market signaling an imminent recession. We’re bracing for a bear market, and providing an update on some of the recommendations in The Big Secret portfolio.
When the King of Bankruptcy Wilbur Ross and Donald Trump negotiated the terms of a distressed-bond settlement, Ross’ knowledge of the casino operator’s ability to pay helped him win the deal.
Coal – yes, coal – will save today’s computing revolution. One U.S. producer of this throwback energy source is thriving, despite the best efforts of American policymakers to bankrupt the industry. Wall Street hates this stock, so you can buy it for a bargain.
The Activist Investor goal is to buy shares before they soar: investing in activist campaign stocks that have been sold off to their lowest levels… then benefit as these companies begin to turn around and prosper.
This month’s issue of Biotech Frontiers focuses on a fast follower whose stock is poised to soar because it has a better version of a successful medicine… which it has also, strategically, chosen to make available at a better price.
While it doesn’t get much attention in the media, this under-the-radar chipmaker is poised to become one of the biggest winners from today’s parallel-computing revolution – and it’s a company Nvidia greatly relies on.
Financial distress persists even when the S&P 500 and other indications seem to be emphatically signaling prosperity – and why this could mean more opportunities to earn excellent returns in coming months.
This promising producer of next-generation digital and power devices caught the eye of an activist investor who is pushing hard to get the company to turn the billions it invested in new plants into exponential revenue growth.
The two companies whose stories we tell this week will continue to dominate the global semiconductor supply chain for years to come – and are the two best ideas to capitalize on today’s parallel-processing revolution.
In this month’s issue, we focus on a drugmaker that has one hidden asset that ties all its other assets together and acts as a value multiplier for them: and it has a spectacular track record of success that traces back to the company’s origins.